Neoadjuvant Gemcitabine Plus Cisplatin With or Without Durvalumab in Resectable Biliary Tract Cancer
Status:
Recruiting
Trial end date:
2023-12-30
Target enrollment:
Participant gender:
Summary
Considering that the poor prognosis of resected biliary tract cancer and negative impact on
the survival outcomes of R1/R2 resection, neoadjuvant chemotherapy may improve R0 resection
rates and the survival outcomes of patients with resectable biliary tract cancer. The
addition of durvalumab to gemcitabine/cisplatin as neoadjuvant chemotherapy may improve the
R0 resection rates compared to gemcitabine/cisplatin in patients with localized biliary tract
cancer. In this phase 2 trial, a total of 45 patients with localized biliary tract cancer
will be 2:1 randomized to durvalumab plus gemcitabine/cisplatin or gemcitabine/cisplatin.